The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD)； cannabidiol acid (CBDA)； cannabigerol (CBG)； cannabigerolic acid (CBGA)； cannabigerol propyl variant (CBGV)； and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG.
